| Name | Title | Contact Details |
|---|
In 2015, five seminal randomized controlled trials were published in the neurovascular space demonstrating endovascular thrombectomy to be the new gold standard for treating large vessel occlusion strokes. During that same year, advancements in artificial intelligence and deep learning made it possible to analyze medical imaging rapidly and accurately. However, despite having proven effective interventions for stroke, most stroke patients were getting treatment late or not at all. At Stanford University, Dr. Chris Mansi (neurosurgeon) and Dr. David Golan (machine learning researcher) identified this problem and together they sought to change it.
At LumiThera, we are committed to developing solutions to prevent vision loss and blindness, improve visual function and stop or slow the progression of blinding diseases of the eye. We will continue to innovate non-invasive approaches to address unmet medical needs. LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company`s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments. Three clinical studies have demonstrated clinical and pathological benefits of PBM in treating subjects with dry AMD. The recent TORPA II clinical trial results demonstrating improvements in clinical outcomes of vision and reduction of pathological “drusen” following imaging analysis were published in December 2016 in ACTA Ophthalmologica, a top peer-reviewed Ophthalmology journal. The company recently completed the LIGHTSITE I clinical trial,a thirty subject dry AMD study partially supported by the National Eye Institute. The Valeda LIght Delivery System is now available for sale in the European Economic Area. The Valeda Light Delivery System is CE Marked. The device is not for sale in the USA.
Bard Electrophysiology is a Lowell, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Barbour County Home Health is a Philippi, WV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
EndoStim is a medical device company focused on the treatment of gastroesophageal reflux disease (GERD) through electrical stimulation of the lower esophageal sphincter. GERD is a condition affects millions of people worldwide and is often not optimally treated despite a maximum drug dosage of medications such as proton pump inhibitors (PPIs). EndoStim’s innovative technology provides a solution addressing the root physiological cause of the disease -- namely a weak or dysfunctional lower esophageal sphincter that allows for reflux into the esophagus.